SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

December 10, 2003

(Date of earliest event reported)

CONNETICS CORPORATION

(Exact name of Registrant as specified in its charter)

Delaware	0-27406	94-3173928
(State or Other Jurisdiction of Incorporation)	(Commission File No.)	(IRS Employer Identification No.)

3290 West Bayshore Road, Palo Alto, California 94303

(Address of principal executive offices, including zip code)

(650) 843-2800

(Registrant’s telephone number, including area code)

TABLE OF CONTENTS

	Item 5. Other Events.
	Item 7. Financial Statements and Exhibits.
SIGNATURES
EXHIBIT INDEX
EXHIBIT 99.1

Item 5. Other Events.

     On December 10, 2003, Connetics Corporation announced that it received notification from the FDA that no user fee is required for the new drug application (NDA) seeking marketing clearance for Extina™ (ketoconazole 2%) Foam. In April, Connetics announced positive results from its Phase III clinical trial with Extina versus Nizoral ™. Connetics submitted an NDA for Extina in July.

     A copy of the press release announcing this event is attached to this Report as Exhibit 99.1 and is incorporated into this report by this reference.

Item 7. Financial Statements and Exhibits.

     (c) Exhibits.

          99.1 Press Release dated December 10, 2003.

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	CONNETICS CORPORATION
	By:	/s/ Katrina J. Church
		Katrina J. Church Executive Vice President, General Counsel and Secretary
Date:  December 11, 2003

EXHIBIT INDEX

Exhibit
Number	Description
99.1	Press Release dated December 10, 2003